Company news

Regenxbio Inc. news in 2025

Regenxbio Inc.'s news releases, calls and decks from 2025, newest first.

View company

REGENXBIO to Present at the 44th Annual J.P. Morgan Healthcare Conference

December 17, 2025

REGENXBIO to Participate in Upcoming Investor Conference

November 24, 2025

REGENXBIO Reports Third Quarter 2025 Financial Results and Operational Highlights

November 5, 2025

REGENXBIO Announces Completion of Pivotal Enrollment and Initiates Commercial Production in Duchenne Gene Therapy Program

October 29, 2025

REGENXBIO to Host Conference Call on November 6 to Discuss Third Quarter 2025 Financial Results and Operational Highlights

October 28, 2025

REGENXBIO to Participate in Upcoming Investor Conferences

October 14, 2025

REGENXBIO Announces Presentation at the American Academy of Ophthalmology 2025 Annual Meeting

October 8, 2025

REGENXBIO Announces Completion of Enrollment in Pivotal Trials of Subretinal Surabgene Lomparvovec for Wet AMD

October 5, 2025

REGENXBIO Announces Presentation at the World Muscle Society

September 28, 2025

REGENXBIO Presents Positive Twelve-Month Pivotal Data from Phase I/II/III CAMPSIITE® Trial of RGX-121 for Treatment of MPS II

September 4, 2025

REGENXBIO Announces FDA Review Extension of BLA for RGX-121 to Treat Patients with MPS II

August 17, 2025

REGENXBIO Reports Second Quarter 2025 Financial Results and Operational Highlights

August 6, 2025

REGENXBIO Announces Pivotal Program for Surabgene Lomparvovec in Diabetic Retinopathy

August 6, 2025

REGENXBIO to Host Conference Call on August 7 to Discuss Second Quarter 2025 Financial Results and Operational Highlights

July 30, 2025

REGENXBIO Announces Publication of Preclinical Results Demonstrating Functional Benefits of Novel Microdystrophin Construct in RGX-202 Investigational Gene Therapy for Duchenne Muscular Dystrophy

July 9, 2025

REGENXBIO reports new positive functional data from Phase I/II affinity Duchenne® trial of RGX-202

June 4, 2025

REGENXBIO to Host Webcast Discussing Interim Functional Data from the Phase I/II AFFINITY DUCHENNE® Trial of RGX-202

June 1, 2025

REGENXBIO Announces Strategic Royalty Monetization Agreement for Up to $250 Million

May 18, 2025

REGENXBIO Announces FDA Acceptance and Priority Review of the BLA for RGX-121 for MPS II

May 12, 2025

REGENXBIO Reports First Quarter 2025 Financial Results and Recent Operational Highlights

May 11, 2025

REGENXBIO Announces Presentations at the American Society of Gene & Cell Therapy 28th Annual Meeting

May 7, 2025

REGENXBIO to Host Conference Call on May 12 to Discuss First Quarter 2025 Financial Results and Recent Operational Highlights

April 29, 2025

REGENXBIO reports positive biomarker data from affinity Duchenne® trial of RGX-202 gene therapy

March 18, 2025

REGENXBIO Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Operational Updates

March 12, 2025

REGENXBIO Announces Presentations at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference

March 9, 2025

REGENXBIO Announces Closing of Strategic Partnership with Nippon Shinyaku for MPS Diseases

March 3, 2025

REGENXBIO to Host Conference Call on March 13 to Discuss Fourth Quarter and Full Year 2024 Financial Results and Recent Operational Highlights

February 25, 2025

REGENXBIO Announces Presentations of RGX-121 at the 21st Annual WORLDSymposium 2025

January 29, 2025

REGENXBIO and Nippon Shinyaku Announce Exclusive Partnership to Develop and Commercialize RGX-121 and RGX-111 for MPS Diseases

January 13, 2025

AbbVie and REGENXBIO Announce Updates on the ABBV-RGX-314 Clinical Program

January 12, 2025

Calls in 2025

Decks in 2025